QUIDEL ACQUIRES MARKETING RIGHTS TO SAFEPLAN OTC FERTILITY TEST
This article was originally published in The Tan Sheet
Executive Summary
QUIDEL ACQUIRES MARKETING RIGHTS TO SAFEPLAN OTC FERTILITY TEST from Dutch pharmaceutical firm Akzo in a deal announced Jan. 4. Under terms of the agreement, Akzo will transfer worldwide marketing fights to Quidel in exchange for an undisclosed transfer fee and royalty payments on net product sales. Quidel will also provide Akzo with the option to co-market the product in exchange for an undisclosed sum upon FDA marketing clearance of SafePlan and upon initial sales of the product in the U.S.